John D Groopman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9426659/publications.pdf

Version: 2024-02-01

239 papers

14,709 citations

68 h-index 22832 112 g-index

244 all docs 244 docs citations

times ranked

244

11671 citing authors

#	Article	IF	CITATIONS
1	Mycotoxins were not associated with environmental enteropathy in a cohort of Tanzanian children. Risk Analysis, 2023, 43, 860-866.	2.7	o
2	Longitudinal Assessment of Prenatal, Perinatal, and Early-Life Aflatoxin B1 Exposure in 828 Mother–Child Dyads from Bangladesh and Malawi. Current Developments in Nutrition, 2022, 6, nzab153.	0.3	5
3	Associations between aflatoxin B 1 â€albumin adduct levels with metabolic conditions in Guatemala: A crossâ€sectional study. Health Science Reports, 2022, 5, e495.	1.5	2
4	Assessing the Validity of Normalizing Aflatoxin B1-Lysine Albumin Adduct Biomarker Measurements to Total Serum Albumin Concentration across Multiple Human Population Studies. Toxins, 2022, 14, 162.	3.4	5
5	Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico. Salud Publica De Mexico, 2022, 64, 35-40.	0.4	2
6	Frequency of the <scp><i>PNPLA3</i></scp> rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population. Liver International, 2022, 42, 1470-1474.	3.9	3
7	Circulating bile acid concentrations and nonâ€alcoholic fatty liver disease in Guatemala. Alimentary Pharmacology and Therapeutics, 2022, 56, 321-329.	3.7	12
8	Constructing a Plasma Nutriproteome for Population Assessment: Analytical Considerations. Current Developments in Nutrition, 2022, 6, 770.	0.3	0
9	Letter: is it appropriate to use a fatty liver index >60 as an alternative criterion for nonâ€alcoholic fatty liver disease? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 378-379.	3.7	0
10	Letter: association of circulating bile acid concentrations and nonâ€alcoholic fatty liver disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 374-375.	3.7	2
11	Editorial: higher levels of certain serum bile acids in nonâ€alcoholic fatty liver disease–new insights from Guatemala.Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 361-362.	3.7	0
12	Aflatoxin exposure was not associated with childhood stunting: results from a birth cohort study in a resource-poor setting of Dhaka, Bangladesh. Public Health Nutrition, 2021, 24, 3361-3370.	2.2	10
13	The association of sex steroid hormone concentrations with nonâ€alcoholic fatty liver disease and liver enzymes in US men. Liver International, 2021, 41, 300-310.	3.9	30
14	Changing Etiology and Epidemiology of Human Liver Cancer. , 2021, , 13-29.		0
15	Liver cancer mortality over six decades in an epidemic area: what we have learned. PeerJ, 2021, 9, e10600.	2.0	13
16	Biomonitoring of Ambient Outdoor Air Pollutant Exposure in Humans Using Targeted Serum Albumin Adductomics. Chemical Research in Toxicology, 2021, 34, 1183-1196.	3.3	9
17	Environmental Pollutants, Mucosal Barriers, and Pathogen Susceptibility; The Case for Aflatoxin B1 as a Risk Factor for HIV Transmission and Pathogenesis. Pathogens, 2021, 10, 1229.	2.8	1
18	Aflatoxin and the aetiology of liver cancer and its implications for Guatemala. World Mycotoxin Journal, 2021, 14, 305-317.	1.4	9

#	Article	IF	CITATIONS
19	Revisiting the tumorigenesis timeline with a data-driven generative model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 857-864.	7.1	44
20	Associations between <i>Helicobacter pylori</i> with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter, 2020, 25, e12756.	3.5	16
21	Aflatoxin B ₁ exposure and liver cirrhosis in Guatemala: a case–control study. BMJ Open Gastroenterology, 2020, 7, e000380.	2.7	14
22	Improving nutrition and immunity with dry chain and integrated pest management food technologies in LMICs. Lancet Planetary Health, The, 2020, 4, e259-e260.	11.4	1
23	Analysis of <scp><i>TP53</i></scp> aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A crossâ€sectional study (2016â€2017). Health Science Reports, 2020, 3, e155.	1.5	4
24	Detection and Concentration of Plasma Aflatoxin Is Associated With Detection of Oncogenic Human Papillomavirus in Kenyan Women. Open Forum Infectious Diseases, 2019, 6, .	0.9	11
25	Serum miRâ€182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats. Molecular Carcinogenesis, 2019, 58, 2017-2025.	2.7	9
26	Dose-dependent detoxication of the airborne pollutant benzene in a randomized trial of broccoli sprout beverage in Qidong, China. American Journal of Clinical Nutrition, 2019, 110, 675-684.	4.7	25
27	Mobilization of Environmental Toxicants Following Bariatric Surgery. Obesity, 2019, 27, 1865-1873.	3.0	13
28	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Research, 2019, 79, 4326-4330.	0.9	99
29	Inflammation throughout pregnancy and fetal growth restriction in rural Nepal. Epidemiology and Infection, 2019, 147, e258.	2.1	10
30	Qidong: a crucible for studies on liver cancer etiology and prevention. Cancer Biology and Medicine, 2019, 16, 24.	3.0	26
31	Association between aflatoxin-albumin adduct levels and tortilla consumption in Guatemalan adults. Toxicology Reports, 2019, 6, 465-471.	3.3	19
32	Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001–2010. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1331-1338.	2.5	10
33	Environmental health in the biology century: Transitions from population to personalized prevention. Experimental Biology and Medicine, 2019, 244, 728-733.	2.4	4
34	Broccoli sprout beverage is safe for thyroid hormonal and autoimmune status: Results of a 12-week randomized trial. Food and Chemical Toxicology, 2019, 126, 1-6.	3 . 6	35
35	Aflatoxin exposure in children living in Mirpur, Dhaka: data from MAL-ED companion study. Journal of Exposure Science and Environmental Epidemiology, 2019, 29, 655-662.	3.9	17
36	High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 191-200.	2.6	17

#	Article	IF	CITATIONS
37	Aflatoxin-Guanine DNA Adducts and Oxidatively Induced DNA Damage in Aflatoxin-Treated Mice <i>iin Vivo</i> as Measured by Liquid Chromatography-Tandem Mass Spectrometry with Isotope Dilution. Chemical Research in Toxicology, 2019, 32, 80-89.	3.3	30
38	Plasma proteome correlates of lipid and lipoprotein: biomarkers of metabolic diversity and inflammation in children of rural Nepal. Journal of Lipid Research, 2019, 60, 149-160.	4.2	6
39	Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology, 2019, 69, 1803-1815.	7.3	195
40	Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV Journal of Clinical Oncology, 2019, 37, 5530-5530.	1.6	1
41	Novel Plasma Proteins in Nepalese School-aged Children are Associated with a Small Head Size at Birth. Scientific Reports, 2018, 8, 6390.	3.3	5
42	Plasma proteins associated with circulating carotenoids in Nepalese school-aged children. Archives of Biochemistry and Biophysics, 2018, 646, 153-160.	3.0	13
43	Exposure to aflatoxin and fumonisin in children at risk for growth impairment in rural Tanzania. Environment International, 2018, 115, 29-37.	10.0	111
44	Unique pulmonary immunotoxicological effects of urban PM are not recapitulated solely by carbon black, diesel exhaust or coal fly ash. Environmental Research, 2018, 161, 304-313.	7.5	26
45	Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer. Hepatoma Research, 2018, 4, 4.	1.5	12
46	Aflatoxins., 2018,,.		2
46	Aflatoxins. , 2018, , . Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention. , 2018, , 143-169.		2
		0.0	
47	Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention., 2018, , 143-169. Protective role of NRF2 in hepatic carcinogenesis. Proceedings for Annual Meeting of the Japanese	0.0	2
47	Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention., 2018,, 143-169. Protective role of NRF2 in hepatic carcinogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY15-2. Chronic aflatoxin exposure in children living in Bhaktapur, Nepal: Extension of the MAL-ED study.		0
48	Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention., 2018, , 143-169. Protective role of NRF2 in hepatic carcinogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY15-2. Chronic aflatoxin exposure in children living in Bhaktapur, Nepal: Extension of the MAL-ED study. Journal of Exposure Science and Environmental Epidemiology, 2017, 27, 106-111. Profound changes in miRNA expression during cancer initiation by aflatoxin B⟨sub⟩1⟨/sub⟩ and their abrogation by the chemopreventive triterpenoid CDDOâ€im. Molecular Carcinogenesis, 2017, 56,	3.9	0 16
47 48 49 50	Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention., 2018, , 143-169. Protective role of NRF2 in hepatic carcinogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY15-2. Chronic aflatoxin exposure in children living in Bhaktapur, Nepal: Extension of the MAL-ED study. Journal of Exposure Science and Environmental Epidemiology, 2017, 27, 106-111. Profound changes in miRNA expression during cancer initiation by aflatoxin B ₁ and their abrogation by the chemopreventive triterpenoid CDDOâ€im. Molecular Carcinogenesis, 2017, 56, 2382-2390. The Plasma Proteome Is Associated with Anthropometric Status of Undernourished Nepalese	3.9 2.7	2 0 16 31
47 48 49 50	Aflatoxin Exposure, Human Liver Cancer Risk, and Chemoprevention., 2018, , 143-169. Protective role of NRF2 in hepatic carcinogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY15-2. Chronic aflatoxin exposure in children living in Bhaktapur, Nepal: Extension of the MAL-ED study. Journal of Exposure Science and Environmental Epidemiology, 2017, 27, 106-111. Profound changes in miRNA expression during cancer initiation by aflatoxin B⟨sub⟩1⟨/sub⟩ and their abrogation by the chemopreventive triterpenoid CDDOâ€im. Molecular Carcinogenesis, 2017, 56, 2382-2390. The Plasma Proteome Is Associated with Anthropometric Status of Undernourished Nepalese School-Aged Children. Journal of Nutrition, 2017, 147, jn243014.	3.9 2.7 2.9	2 0 16 31

#	Article	IF	Citations
55	Comparison of Metabolic Risk Factors for Liver Cancer Among Men and Women in Guatemala. Journal of Global Oncology, 2017, 3, 10s-11s.	0.5	2
56	Plasma Selenium Protein P Isoform 1 (SEPP1): A Predictor of Selenium Status in Nepalese Children Detected by Plasma Proteomics. International Journal for Vitamin and Nutrition Research, 2017, 87, 1-10.	1.5	7
57	Aflatoxin exposure during the first 36 months of life was not associated with impaired growth in Nepalese children: An extension of the MAL-ED study. PLoS ONE, 2017, 12, e0172124.	2.5	48
58	Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS ONE, 2017, 12, e0189255.	2.5	47
59	Biological Systems of Vitamin K: A Plasma Nutriproteomics Study of Subclinical Vitamin K Deficiency in 500 Nepalese Children. OMICS A Journal of Integrative Biology, 2016, 20, 214-223.	2.0	13
60	General intelligence is associated with subclinical inflammation in Nepalese children: A population-based plasma proteomics study. Brain, Behavior, and Immunity, 2016, 56, 253-263.	4.1	25
61	Environmental Carcinogens and Risk for Human Liver Cancer. , 2016, , 25-41.		0
62	Serial Free Bisphenol A and Bisphenol A Glucuronide Concentrations inÂNeonates. Journal of Pediatrics, 2015, 167, 64-69.	1.8	15
63	Association of Aflatoxin With Gallbladder Cancer in Chile. JAMA - Journal of the American Medical Association, 2015, 313, 2075.	7.4	53
64	Dietary aflatoxin-induced stunting in a novel rat model: evidence for toxin-induced liver injury and hepatic growth hormone resistance. Pediatric Research, 2015, 78, 120-127.	2.3	25
65	Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally. Journal of the National Cancer Institute, 2015, 107, 1-5.	6.3	34
66	Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali. BMC Infectious Diseases, 2015, 15, 180.	2.9	14
67	A Plasma α-Tocopherome Can Be Identified from Proteins Associated with Vitamin E Status in School-Aged Children of Nepal. Journal of Nutrition, 2015, 145, 2646-2656.	2.9	19
68	Prenatal exposure of mice to the human liver carcinogen aflatoxin B ₁ reveals a critical window of susceptibility to genetic change. International Journal of Cancer, 2015, 136, 1254-1262.	5.1	28
69	Sulforaphane, a cancer chemopreventive agent, induces pathways associated with membrane biosynthesis in response to tissue damage by aflatoxin B1. Toxicology and Applied Pharmacology, 2015, 282, 52-60.	2.8	23
70	Plasma Proteome Biomarkers of Inflammation in School Aged Children in Nepal. PLoS ONE, 2015, 10, e0144279.	2.5	22
71	Novel Natural Mutations in the Hepatitis B Virus Reverse Transcriptase Domain Associated with Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e94864.	2.5	16
72	Rapid and Sustainable Detoxication of Airborne Pollutants by Broccoli Sprout Beverage: Results of a Randomized Clinical Trial in China. Cancer Prevention Research, 2014, 7, 813-823.	1.5	151

#	Article	IF	Citations
73	Genetic or Pharmacologic Activation of Nrf2 Signaling Fails to Protect Against Aflatoxin Genotoxicity in Hypersensitive GSTA3 Knockout Mice. Toxicological Sciences, 2014, 139, 293-300.	3.1	22
74	Aflatoxin exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B1-lysine albumin biomarkers. Food and Chemical Toxicology, 2014, 74, 184-189.	3.6	97
75	Dietary Acrylamide and Human Cancer: A Systematic Review of Literature. Nutrition and Cancer, 2014, 66, 774-790.	2.0	104
76	Early Life Metabolism of Bisphenol A: A Systematic Review of the Literature. Current Environmental Health Reports, 2014, 1, 90-100.	6.7	38
77	Complete Protection against Aflatoxin B1-Induced Liver Cancer with a Triterpenoid: DNA Adduct Dosimetry, Molecular Signature, and Genotoxicity Threshold. Cancer Prevention Research, 2014, 7, 658-665.	1.5	63
78	Public Health Impacts of Foodborne Mycotoxins. Annual Review of Food Science and Technology, 2014, 5, 351-372.	9.9	439
79	Association between <i>TP53</i> R249S mutation and polymorphisms in <itp53< i=""> intron 1 in hepatocellular carcinoma. Genes Chromosomes and Cancer, 2013, 52, 912-919.</itp53<>	2.8	10
80	Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Letters, 2013, 331, 46-51.	7.2	23
81	Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis, 2013, 34, 2587-2592.	2.8	34
82	Urinary Free Bisphenol A and Bisphenol A-Glucuronide Concentrations in Newborns. Journal of Pediatrics, 2013, 162, 870-872.	1.8	25
83	Statistical Inference from Multiple iTRAQ Experiments without Using Common Reference Standards. Journal of Proteome Research, 2013, 12, 594-604.	3.7	130
84	The Plasma Proteome Identifies Expected and Novel Proteins Correlated with Micronutrient Status in Undernourished Nepalese Children. Journal of Nutrition, 2013, 143, 1540-1548.	2.9	44
85	Reduced Aflatoxin Exposure Presages Decline in Liver Cancer Mortality in an Endemic Region of China. Cancer Prevention Research, 2013, 6, 1038-1045.	1.5	125
86	Effects of Antenatal Micronutrient Supplementation on Plasma Protein Profiles in Nepalese Children. FASEB Journal, 2013, 27, 1080.7.	0.5	0
87	TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis, 2012, 33, 1219-1224.	2.8	38
88	A Single Neonatal Exposure to Aflatoxin B1 Induces Prolonged Genetic Damage in Two Loci of Mouse Liver. Toxicological Sciences, 2012, 128, 326-333.	3.1	12
89	Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Carcinogenesis, 2012, 33, 101-107.	2.8	108
90	Keap1–Nrf2 Signaling: A Target for Cancer Prevention by Sulforaphane. Topics in Current Chemistry, 2012, 329, 163-177.	4.0	272

#	Article	IF	Citations
91	Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2012, 29, 249-257.	2.3	104
92	Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis. PLoS ONE, 2012, 7, e37707.	2.5	42
93	Maternal serum proteome changes between the first and third trimester of pregnancy in rural Southern Nepal. Placenta, 2012, 33, 424-432.	1.5	23
94	Chemoprevention of Hepatic Cancer in Aflatoxin Endemic Areas. , 2012, , 339-365.		1
95	Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma. Carcinogenesis, 2011, 32, 63-68.	2.8	30
96	Seasonal Variation in <i>TP53 R249S</i> -Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection. Environmental Health Perspectives, 2011, 119, 1635-1640.	6.0	33
97	Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival. Molecular Carcinogenesis, 2011, 50, 972-980.	2.7	20
98	Aflatoxin: A 50-Year Odyssey of Mechanistic and Translational Toxicology. Toxicological Sciences, 2011, 120, S28-S48.	3.1	519
99	Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis, 2011, 32, 860-865.	2.8	31
100	Bioavailability of Sulforaphane from Two Broccoli Sprout Beverages: Results of a Short-term, Cross-over Clinical Trial in Qidong, China. Cancer Prevention Research, 2011, 4, 384-395.	1.5	164
101	Aflatoxin B1-DNA Adduct Formation and Mutagenicity in Livers of Neonatal Male and Female B6C3F1 Mice. Toxicological Sciences, 2011, 122, 38-44.	3.1	67
102	Sulforaphane-Mediated Reduction of Aflatoxin B1-N7-Guanine in Rat Liver DNA: Impacts of Strain and Sex. Toxicological Sciences, 2011, 121, 57-62.	3.1	20
103	Aflatoxin and Hepatocellular Carcinoma. , 2011, , 113-133.		4
104	Comparison Study on the Complete Sequence of Hepatitis B Virus Identifies New Mutations in Core Gene Associated with Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2623-2630.	2.5	37
105	Is It Time to Advance the Chemoprevention of Environmental Carcinogenesis with Microdosing Trials?. Cancer Prevention Research, 2009, 2, 1003-1007.	1.5	10
106	Transgenic Expression of Aflatoxin Aldehyde Reductase (AKR7A1) Modulates Aflatoxin B1 Metabolism but not Hepatic Carcinogenesis in the Rat. Toxicological Sciences, 2009, 109, 41-49.	3.1	25
107	Prospective Evaluation of Hepatitis B 1762T/1764A Mutations on Hepatocellular Carcinoma Development in Shanghai, China. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 590-594.	2.5	60
108	Environmental Carcinogens and Risk for Human Liver Cancer. , 2009, , 27-53.		0

#	Article	IF	Citations
109	Formation of Two Novel Estrogen Guanine Adducts and HPLC/MS Detection of 4-Hydroxyestradiol- <i>N</i> ⁷ -Guanine in Human Urine. Chemical Research in Toxicology, 2008, 21, 1622-1630.	3.3	15
110	Quantification of Sulforaphane Mercapturic Acid Pathway Conjugates in Human Urine by High-Performance Liquid Chromatography and Isotope-Dilution Tandem Mass Spectrometry. Chemical Research in Toxicology, 2008, 21, 1991-1996.	3.3	60
111	Quantification of Urinary Aflatoxin B ₁ Dialdehyde Metabolites Formed by Aflatoxin Aldehyde Reductase Using Isotope Dilution Tandem Mass Spectrometry. Chemical Research in Toxicology, 2008, 21, 752-760.	3.3	25
112	Long-term Stability of Human Aflatoxin B1 Albumin Adducts Assessed by Isotope Dilution Mass Spectrometry and High-Performance Liquid Chromatography–Fluorescence. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1436-1439.	2.5	62
113	Protection Against Aflatoxin B $<$ sub $>$ 1 $<$ /sub $>$ -Induced Cytotoxicity by Expression of the Cloned Aflatoxin B $<$ sub $>$ 1 $<$ /sub $>$ -Aldehyde Reductases Rat AKR7A1 and Human AKR7A3. Chemical Research in Toxicology, 2008, 21, 1134-1142.	3.3	32
114	Protective Interventions to Prevent Aflatoxin-Induced Carcinogenesis in Developing Countries. Annual Review of Public Health, 2008, 29, 187-203.	17.4	232
115	Human Aflatoxin Albumin Adducts Quantitatively Compared by ELISA, HPLC with Fluorescence Detection, and HPLC with Isotope Dilution Mass Spectrometry. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1653-1657.	2.5	71
116	A Novel Acetylenic Tricyclic <i>bis</i> -(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin. Cancer Research, 2008, 68, 6727-6733.	0.9	49
117	Natural chlorophyll inhibits aflatoxin B1-induced multi-organ carcinogenesis in the rat. Carcinogenesis, 2007, 28, 1294-1302.	2.8	88
118	Acceleration to Death from Liver Cancer in People with Hepatitis B Viral Mutations Detected in Plasma by Mass Spectrometry. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1213-1218.	2.5	16
119	Measurement of Aflatoxin and Aflatoxin Metabolites in Urine by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2007, 31, 150-156.	2.8	15
120	Workgroup Report: Public Health Strategies for Reducing Aflatoxin Exposure in Developing Countries. Environmental Health Perspectives, 2006, 114, 1898-1903.	6.0	393
121	Quantification of Aflatoxin-B1-N7-Guanine in Human Urine by High-Performance Liquid Chromatography and Isotope Dilution Tandem Mass Spectrometry1. Chemical Research in Toxicology, 2006, 19, 1191-1195.	3.3	93
122	DNA Adduct Formation by 2,6-Dimethyl-, 3,5-Dimethyl-, and 3-Ethylaniline in Vivo in Mice. Chemical Research in Toxicology, 2006, 19, 1086-1090.	3.3	35
123	Quantitative Analysis and Chronic Dosimetry of the Aflatoxin B1Plasma Albumin Adduct Lys-AFB1in Rats by Isotope Dilution Mass Spectrometry. Chemical Research in Toxicology, 2006, 19, 44-49.	3.3	52
124	Urinary biomarkers of 1,3-butadiene in environmental settings using liquid chromatography isotope dilution tandem mass spectrometry. Chemico-Biological Interactions, 2006, 160, 70-79.	4.0	31
125	Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole. Cancer Research, 2006, 66, 2488-2494.	0.9	186
126	Quantitative Comparison of Aflatoxin B1 Serum Albumin Adducts in Humans by Isotope Dilution Mass Spectrometry and ELISA. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 823-826.	2.5	63

#	Article	IF	Citations
127	Aflatoxin and hepatitis B virus biomarkers: A paradigm for complex environmental exposures and cancer risk. Cancer Biomarkers, 2005, 1, 5-14.	1.7	85
128	Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicology and Applied Pharmacology, 2005, 206, 131-137.	2.8	98
129	Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 2203-2210.	1.5	68
130	Quantitative Analysis of Plasma TP53 249Ser-Mutated DNA by Electrospray Ionization Mass Spectrometry. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2956-2962.	2.5	40
131	Absence of TP53 Codon 249 Mutations in Young Guinean Children with High Aflatoxin Exposure. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2053-2055.	2.5	29
132	Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in a Randomized Clinical Trial in He Zuo Township, Qidong, People's Republic of China. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2605-2613.	2.5	287
133	Hepatitis B 1762T/1764A Mutations, Hepatitis C Infection, and Codon 249 p53 Mutations in Hepatocellular Carcinomas from Thailand. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 380-384.	2.5	55
134	Human exposure monitoring and evaluation in the Arctic: the importance of understanding exposures to the development of public health policy Environmental Health Perspectives, 2004, 112, 113-120.	6.0	25
135	A Summary of the Workshop "Applying Biomarkers to Occupational Health Practice― Journal of Occupational and Environmental Hygiene, 2004, 1, D57-D60.	1.0	0
136	Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3575-3580.	7.1	157
137	Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Research, 2004, 32, e53-e53.	14.5	31
138	Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology, 2004, 39, 433-443.	7.3	61
139	Synthesis of 5,5,6,6-D4-L-lysine-aflatoxin Bl for use as a mass spectrometric internal standard. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 807-815.	1.0	24
140	Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 2004, 127, S310-S318.	1.3	144
141	Toxicological resources for cumulative risk: an example with hazardous air pollutants. Regulatory Toxicology and Pharmacology, 2004, 40, 305-311.	2.7	24
142	Decreased oxidative DNA damage and accelerated cell turnover in woodchuck hepatitis virus infected liver. Hepatology Research, 2003, 25, 254-262.	3.4	2
143	Translational strategies for cancer prevention in liver. Nature Reviews Cancer, 2003, 3, 321-329.	28.4	191
144	DNA Methylation as a Cancerâ€Specific Biomarker. Annals of the New York Academy of Sciences, 2003, 983, 286-297.	3.8	33

#	Article	IF	Citations
145	Identification of Aflatoxin M1-N7-Guanine in Liver and Urine of Tree Shrews and Rats Following Administration of Aflatoxin B1. Chemical Research in Toxicology, 2003, 16, 1174-1180.	3.3	33
146	Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis, 2003, 24, 1657-1663.	2.8	87
147	The Design of a Randomized, Placebo-Controlled Trial of Celecoxib in Preprostatectomy Men with Clinically Localized Adenocarcinoma of the Prostate. Clinical Prostate Cancer, 2002, 1, 182-187.	2.1	5
148	Sensitivity of electrospray ionization mass spectrometry detection of codon 249 mutations in the p53 gene compared with RFLP. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1126-9.	2.5	8
149	Strategies for chemoprevention of liver cancer. European Journal of Cancer Prevention, 2002, 11 Suppl 2, S58-64.	1.3	12
150	Liquid Chromatography Electrospray-Mass Spectrometry of Urinary Aflatoxin Biomarkers: Characterization and Application to Dosimetry and Chemoprevention in Rats. Chemical Research in Toxicology, 2001, 14, 919-926.	3.3	53
151	Reduction of Aflatoxin B1 Dialdehyde by Rat and Human Aldo-keto Reductases. Chemical Research in Toxicology, 2001, 14, 727-737.	3.3	64
152	Immunoaffinity-based biosensor for polycyclic aromatic hydrocarbons. , 2001, , .		0
153	Molecular Epidemiology and Biomarkers. , 2001, , 271-298.		2
154	Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Digestive Diseases and Sciences, 2001, 46, 2173-2178.	2.3	39
155	Preneoplastic Prostate Lesions. Annals of the New York Academy of Sciences, 2001, 952, 135-144.	3.8	93
156	Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 480-481, 305-315.	1.0	219
157	Development of Aflatoxin B 1 -Lysine Adduct Monoclonal Antibody for Human Exposure Studies. Applied and Environmental Microbiology, 2001, 67, 2712-2717.	3.1	36
158	Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14601-14606.	7.1	273
159	Title is missing!. Nature Genetics, 2001, 28, 29-35.	21.4	278
160	An automated, handheld biosensor for aflatoxin. Biosensors and Bioelectronics, 2000, 14, 841-848.	10.1	71
161	Mass spectrometry for genotyping: an emerging tool for molecular medicine. Trends in Molecular Medicine, 2000, 6, 271-276.	2.6	34
162	Reduction of aflatoxin B1 adduct biomarkers by oltipraz in the tree shrew (Tupaia belangeri chinensis). Cancer Letters, 2000, 154, 79-83.	7.2	25

#	Article	IF	CITATIONS
163	Enzyme-Mediated Dialdehyde Formation:  An Alternative Pathway for Benzo[a]pyrene 7,8-Dihydrodiol Bioactivation. Chemical Research in Toxicology, 2000, 13, 1174-1180.	3.3	8
164	Elevated HPRT mutation frequencies in aflatoxin-exposed residents of Daxin, Qidong County, People's Republic of China. Carcinogenesis, 1999, 20, 2181-2184.	2.8	13
165	Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells. Carcinogenesis, 1999, 20, 479-483.	2.8	75
166	Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China. Journal of the National Cancer Institute, 1999, 91, 347-354.	6.3	293
167	The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight?. Carcinogenesis, 1999, 20, 1-11.	2.8	126
168	cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis, 1999, 20, 1215-1223.	2.8	77
169	Does Aflatoxin B1Play a Role in the Etiology of Hepatocellular Carcinoma in the United States?. Nutrition and Cancer, 1999, 35, 27-33.	2.0	14
170	Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. British Journal of Cancer, 1999, 80, 59-66.	6.4	83
171	Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*. Clinical Pharmacology and Therapeutics, 1999, 66, 224-231.	4.7	123
172	Aflatoxin and liver cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, 545-555.	2.4	72
173	DNA damage by mycotoxins. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 424, 167-181.	1.0	300
174	Development of Cancer Chemopreventive Agents: Oltipraz as a Paradigm. Chemical Research in Toxicology, 1999, 12, 113-126.	3.3	146
175	Evaluation of Exposure and Effects in Human Session: Biomarkers in Environmental Health Research & Environmental Chemical Toxicology, 1999, 22, 1-14.	2.3	3
176	Genotyping by mass spectrometric analysis of short DNA fragments. Nature Biotechnology, 1998, 16, 1352-1356.	17.5	112
177	Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 402, 165-172.	1.0	37
178	Commentary: Approaches to Environmental Exposure Assessment in Children. Environmental Health Perspectives, 1998, 106, 827.	6.0	33
179	Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11915-11920.	7.1	174
180	Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450- expressing human liver cell lines. Carcinogenesis, 1997, 18, 1291-1297.	2.8	179

#	Article	IF	Citations
181	Synthesis and Characterization of Aflatoxin B1Mercapturic Acids and Their Identification in Rat Urine. Chemical Research in Toxicology, 1997, 10, 1144-1151.	3.3	47
182	Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. Journal of Cellular Biochemistry, 1997, 67, 166-173.	2.6	18
183	SHORT COMMUNICATION: Inhibition of aflatoxin M1 excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis, 1996, 17, 1385-1388.	2.8	26
184	Increased oxidative DNA damage in livers of 2,3,7,8-tetrachlorodibenzo-p-dioxin treated intact but not ovariectomized rats. Cancer Letters, 1996, 98, 219-225.	7.2	78
185	Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Canadian Journal of Physiology and Pharmacology, 1996, 74, 203-209.	1.4	39
186	Benzene exposure, assessed by urinary trans, trans-muconic acid, in urban children with elevated blood lead levels Environmental Health Perspectives, 1996, 104, 318-323.	6.0	43
187	Carcinogen-DNA and protein adducts: Biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. Journal of Cellular Biochemistry, 1996, 63, 85-91.	2.6	11
188	An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis, 1996, 17, 1007-1012.	2.8	117
189	Molecular biomarkers for aflatoxins and their application to human liver cancer. Pharmacogenetics and Genomics, 1995, 5, S171-S176.	5.7	9
190	Biomarkers for assessing environmental exposure to carcinogens in the diet. American Journal of Clinical Nutrition, 1995, 61, 710S-720S.	4.7	28
191	Biomarkers and Mechanistic Approaches in Environmental Epidemiology. Annual Review of Public Health, 1995, 16, 83-103.	17.4	34
192	Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis, 1995, 16, 1769-1773.	2.8	42
193	Interindividual differences in the concentration of 1-hydroxypyrene-glucuronide in urine and polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells after charbroiled beef consumption. Carcinogenesis, 1995, 16, 1079-1085.	2.8	129
194	Molecular epidemiology and human risk monitoring. Toxicology Letters, 1995, 82-83, 763-769.	0.8	12
195	Respiratory Aflatoxicosis: Suppression of Pulmonary and Systemic Host Defenses in Rats and Mice. Toxicology and Applied Pharmacology, 1994, 125, 198-205.	2.8	86
196	Quantitative carcinogenesis and dosimetry in rainbow trout for aflatoxin B1 and aflatoxicol, two aflatoxins that form the same DNA adduct. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1994, 313, 25-38.	0.4	40
197	WorkshopC: The Ambient Environment - Monitoring Effects and Initiating Change. Preventive Medicine, 1994, 23, 554-555.	3.4	1
198	Identification of 1-hydroxypyrene glucuronide as a major pyrene metabolite in human urine by synchronous fluorescence spectroscopy and gas chromatography-mass spectrometry. Carcinogenesis, 1994, 15, 483-487.	2.8	103

#	Article	IF	Citations
199	Carcinogen-DNA and Protein Adducts as Intermediate Biomarkers for Human Chemoprotection Trials. Advances in Experimental Medicine and Biology, 1994, 354, 149-160.	1.6	3
200	Molecular Dosimetry Methods for Assessing Human Aflatoxin Exposures. , 1994, , 259-279.		10
201	Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 1993, 54, 621-629.	4.7	127
202	The direct glucuronidation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human and rabbit liver microsomes. Chemical Research in Toxicology, 1993, 6, 846-851.	3.3	45
203	Molecular biomarkers for human chemical carcinogen exposures. Chemical Research in Toxicology, 1993, 6, 764-770.	3.3	43
204	Diet and carcinogenesis. Carcinogenesis, 1993, 14, 2205-2217.	2.8	197
205	Quantitative analysis of aflatoxin-albumin adducts. Carcinogenesis, 1993, 14, 1203-1208.	2.8	29
206	Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5123-5127.	7.1	222
207	Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans Environmental Health Perspectives, 1993, 99, 107-113.	6.0	94
208	Chemoprotection by Inducers of Electrophile Detoxication Enzymes., 1993, 61, 127-136.		13
209	Aflatoxin B1 – DNA adduct formation in rat liver following exposure by aerosol inhalation. Carcinogenesis, 1992, 13, 1031-1033.	2.8	25
210	Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenylâ€"DNA adducts and application to immunoaffinity chromatography. Carcinogenesis, 1992, 13, 917-922.	2.8	8
211	Aflatoxrn M1 in human breast milk from The Gambia, West Africa, quantified by combined monoclonal antibody immunoaffinity chromatography and HPLC. Carcinogenesis, 1992, 13, 891-894.	2.8	107
212	Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by l,2-dithiole-3-thione in rats. Carcinogenesis, 1992, 13, 101-106.	2.8	80
213	Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer l,2-dithiole-3-thione. Carcinogenesis, 1992, 13, 95-100.	2.8	94
214	Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, The, 1992, 339, 943-946.	13.7	648
215	Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chemical Research in Toxicology, 1992, 5, 202-210.	3.3	115
216	Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology Environmental Health Perspectives, 1992, 98, 75-80.	6.0	43

#	Article	IF	CITATIONS
217	Aflatoxins isolated by immunoaffinity chromatography from foods consumed in the Gambia, West Africa. Natural Toxins, 1992, 1, 100-105.	1.0	30
218	Mechanisms of chemoprotection by oltipraz. Journal of Cellular Biochemistry, 1992, 50, 167-172.	2.6	30
219	Mechanisms of Chemoprotection against Aflatoxin-Induced Hepatocarcinogenesis by Oltipraz., 1991,, 315-322.		3
220	Immunoaffinity-Based Monitoring of Human Exposure to Aflatoxins in China and Gambia. ACS Symposium Series, 1990, , 207-214.	0.5	1
221	Aflatoxin-DNA adduct formation in chronically dosed rats fed a choline-deficient diet. Carcinogenesis, 1990, 11, 177-180.	2.8	23
222	The aflatoxin â€" lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis, 1990, 11, 2063-2066.	2.8	73
223	Use of Aflatoxin-DNA and Protein Adducts for Human Dosimetry. , 1990, , 325-334.		0
224	Antibody-antigen binding in organic solvents. Biochemical and Biophysical Research Communications, 1989, 158, 80-85.	2.1	77
225	Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat. Toxicology and Applied Pharmacology, 1988, 93, 442-451.	2.8	7 3
226	Aflatoxin Exposure in Human Populations: Measurements and Relationship to Cancer. CRC Critical Reviews in Toxicology, 1988, 19, 113-145.	4.9	196
227	Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis, 1988, 9, 1323-1325.	2.8	183
228	Aflatoxin, A Human Carcinogen: Determination in Foods and Biological Samples by Monoclonal Antibody Affinity Chromatography. Journal of the Association of Official Analytical Chemists, 1988, 71, 861-867.	0.2	28
229	Induction of base substitution mutations by aflatoxin B1 is mucAB dependent in Escherichia coli. Journal of Bacteriology, 1988, 170, 3415-3420.	2.2	35
230	Inhibition of aflatoxin B1 mutagenesis in Salmonella typhimurium and DNA damage in cultured rat and human tracheobronchial tissues by ellagic acid. Carcinogenesis, 1987, 8, 1651-1656.	2.8	71
231	The use of monoclonal antibody affinity columns for assessing DNA damage and repair following exposure to aflatoxin B1., 1987, 34, 321-334.		12
232	Application of Monoclonal Antibodies and Dietary Antioxidant-Based Animal Models to Define Human Exposure to Aflatoxin B1. Progress in Tumor Research, 1987, 31, 52-62.	0.1	3
233	Analytical Methods for Assessing Exposure to 4-Aminobiphenyl Based on Protein Adduct Formation. Journal of Occupational and Environmental Medicine, 1986, 28, 643-646.	1.7	6
234	Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 6492-6496.	7.1	160

#	Article	lF	CITATIONS
235	Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis, 1985, 6, 759-763.	2.8	166
236	High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 7728-7731.	7.1	120
237	Monoclonal antibody to aflatoxin B1-modified DNA detected by enzyme immunoassay Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 4124-4127.	7.1	72
238	In vitro reactions of aflatoxin B1-adducted DNA Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 5445-5449.	7.1	128
239	Short Communication: Interaction of aflatoxin B2 with rat liver DNA and histones in vivo. Carcinogenesis, 1981, 2, 1371-1373.	2.8	9